As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc. reportedly is being eyed by pharma giant Pfizer Inc. for a possible collaboration or even outright acquisition. (BioWorld Today) Read More
